Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daxdilimab Open-Label Extension in SLE
NCT05430854Phase 2Terminated
- Sponsor
- Amgen
- Start
- Jun 2022
- Primary completion
- Oct 2023
- Modality
- Monoclonal Antibodies
- Countries
- 9
01
Overview
A Phase 2 trial of daxdilimab in systemic lupus erythematosus (SLE), sponsored by Amgen. Started Jun 2022; status: terminated.
02
Drugs
daxdilimab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT05430854.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05430854.